NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free RVNC Stock Alerts $4.90 -0.04 (-0.81%) (As of 11:03 AM ET) Add Compare Share Share Today's Range$4.86▼$5.0350-Day Range$4.65▼$7.1452-Week Range$4.57▼$37.98Volume170,193 shsAverage Volume1.82 million shsMarket Capitalization$510.68 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Revance Therapeutics alerts: Email Address Revance Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside180.6% Upside$13.75 Price TargetShort InterestHealthy10.43% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.93Based on 3 Articles This WeekInsider TradingSelling Shares$134,553 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.17) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.83 out of 5 starsMedical Sector38th out of 939 stocksPharmaceutical Preparations Industry17th out of 433 stocks 4.3 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.75, Revance Therapeutics has a forecasted upside of 180.6% from its current price of $4.90.Amount of Analyst CoverageRevance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.43% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Revance Therapeutics has recently decreased by 8.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 3.3 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.Search Interest19 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.MarketBeat Follows8 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $134,553.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($2.17) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Revance Therapeutics Stock (NASDAQ:RVNC)Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesMarch 20, 2024 | insidertrades.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Insider Dwight Moxie Sells 8,125 SharesMarch 27, 2024 | finance.yahoo.comRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 16, 2024 | finance.yahoo.comRVNC Apr 2024 5.000 putMarch 11, 2024 | msn.comRevance stock rises after CEO discloses share purchaseMarch 4, 2024 | markets.businessinsider.comRevance Prices Offering Of 16 Mln Shares At $6.25/Share; Stock DropsMarch 4, 2024 | marketwatch.comRevance Therapeutics Shares Slide After Public OfferingMarch 4, 2024 | markets.businessinsider.comRevance Proposes Public Offering Of $100 Mln Of Shares; Stock Down Over 8% In Pre-marketMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 4, 2024 | msn.comRevance Therapeutics down 7%, prices $100M share offeringMarch 4, 2024 | finance.yahoo.comRevance Announces Pricing of $100.0 Million Public Offering of Common StockMarch 4, 2024 | businesswire.comRevance Announces Proposed Public Offering of Common StockMarch 2, 2024 | finance.yahoo.comUS$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest ResultsMarch 2, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comRevance Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | seekingalpha.comRevance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges RemainFebruary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)February 29, 2024 | finance.yahoo.comQ4 2023 Revance Therapeutics Inc Earnings CallFebruary 29, 2024 | markets.businessinsider.comRevance Therapeutics: Strategic Pivot and Growth Potential Justify Buy RatingFebruary 28, 2024 | finance.yahoo.comRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateFebruary 28, 2024 | finance.yahoo.comRevance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023February 27, 2024 | benzinga.comEarnings Outlook For Revance TherapeuticsFebruary 22, 2024 | benzinga.comRevance Therapeutics Stock (NASDAQ:RVNC), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024February 21, 2024 | businesswire.comRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024February 21, 2024 | businesswire.comRevance to Participate in Upcoming Investor ConferencesFebruary 20, 2024 | finance.yahoo.comHalozyme Therapeutics (HALO) Q4 Earnings Match EstimatesSee More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+178.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-323,990,000.00 Net Margins-138.43% Pretax Margin-138.30% Return on Equity-903.28% Return on Assets-45.78% Debt Debt-to-Equity Ratio14.20 Current Ratio3.80 Quick Ratio3.29 Sales & Book Value Annual Sales$234.04 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value($1.73) per share Price / Book-2.86Miscellaneous Outstanding Shares104,220,000Free Float98,901,000Market Cap$514.85 million OptionableOptionable Beta1.09 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 59)CEO & Director Comp: $1.33MMr. Dustin S. Sjuts (Age 44)President Comp: $911.67kMr. Tobin C. Schilke (Age 49)CFO & Principal Accounting Officer Comp: $753.68kMr. Dwight O. Moxie (Age 47)Chief Legal Officer & General Counsel Comp: $743.77kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSenior Director of Investor Relations & Corporate CommunicationsMs. Taryn ConwayVice President of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer of Global Therapeutics Franchise Lead More ExecutivesKey CompetitorsNkartaNASDAQ:NKTXLyell ImmunopharmaNASDAQ:LYELLexicon PharmaceuticalsNASDAQ:LXRXAlto NeuroscienceNYSE:ANROMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsHighPoint Advisor Group LLCBought 11,157 shares on 3/26/2024Ownership: 0.011%Tobin SchilkeSold 9,361 sharesTotal: $47,179.44 ($5.04/share)Dustin S SjutsSold 9,211 sharesTotal: $46,423.44 ($5.04/share)Dwight MoxieSold 8,125 sharesTotal: $40,950.00 ($5.04/share)Vanguard Group Inc.Bought 278,166 shares on 3/11/2024Ownership: 5.747%View All Insider TransactionsView All Institutional Transactions RVNC Stock Analysis - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price target for 2024? 8 brokerages have issued 1 year price targets for Revance Therapeutics' stock. Their RVNC share price targets range from $9.00 to $20.00. On average, they predict the company's stock price to reach $13.75 in the next twelve months. This suggests a possible upside of 180.6% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2024? Revance Therapeutics' stock was trading at $8.79 at the beginning of 2024. Since then, RVNC shares have decreased by 44.3% and is now trading at $4.90. View the best growth stocks for 2024 here. When is Revance Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RVNC earnings forecast. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.17. The biopharmaceutical company earned $69.80 million during the quarter, compared to the consensus estimate of $64.02 million. Revance Therapeutics had a negative net margin of 138.43% and a negative trailing twelve-month return on equity of 903.28%. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (13.60%), Palo Alto Investors LP (5.96%), Vanguard Group Inc. (5.77%), Vanguard Group Inc. (5.75%), Rubric Capital Management LP (1.66%) and CIBC Asset Management Inc (1.31%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVNC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.